The Buzz Surrounding AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) | Financial Buzz

The Buzz Surrounding AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)

About: 

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020.

With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. 

 

AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

Our Behind the Buzz Show Featuring
AnPac Bio-Medical Science Co., Ltd.:

Our Buzz on the Street Show Featuring
AnPac Bio-Medical Science Co., Ltd.:

Investor Recap:

The Science

Anpac Bio uses proprietary, multi-level multi-parameter screening algorithms to identify cancer

Detects the risks of 26 different types of cancer—often identifying cancer at its early stages: Covering 80% of cancer incidences in China from 2013 to 2018

121 issued patents granted to date around its Cancer Differentiation Analysis (“CDA”) technology

Significant cost advantages compared to other screening technologies

In addition to cancer screening and risk detection, Anpac Bio’s CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.

Early Cancer Screening and Detection
Saves Lives and Reduces Costs

Cancer is a leading cause of mortality and morbidity  around the world.

Because early cancer screening and detection potentially shifts cancer diagnosis and treatment to earlier stages of the disease, it can improve patients’ treatment outcomes.

Early stage treatment regimens typically significantly reduce the patient’s lifetime direct medical cost for cancers. The estimated lifetime cost of treatment for a cancer diagnosed at an advanced stage is roughly twice that of a cancer diagnosed at an early stage.

However, early cancer screening and detection remains one of the most challenging tasks in the medical field, due to the difficulties in finding cancers early, accurately and cost-effectively.

CDA Technology

A multi-cancer screening test and analysis platform to detect and assess overall cancer risk. CDA analyzes biophysical properties in human blood.

CDA Testing Process

Fully Automated Cancer Detection Device from Sample to Data Report

Many liquid-based cancer screening and detection technologies focus on biochemical signals (such as conventional biomarkers), genomic signals (such as ct-DNAs) and CTCs (circulating tumor cells in the blood) and can typically only determine whether or not cancer has occurred at a static point in time.

Anpac Bio’s CDA technology is a platform by which we can assess the overall cancer risk for individuals combined with existing bio-markers tests to identify where the cancer is most likely located at a competitive price point.

Medical & Research Partners

Anpac Bio has partnered with respected medical and research institutions in China and the U.S., conducting multiple research studies. Anpac Bio scientists have published and presented research studies at the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit on Biomedical Sciences, among others.

Target Markets & Competitive Landscape

Application for CDA Technology: AnPac Bio is applicable at all points throughout the cycle.

Many other liquid-based cancer screening and detection technologies focus on biochemical signals (such as conventional biomarkers), genomic signals (such as ct-DNAs) and CTCs (circulating tumor cells in the blood) and can typically only determine whether or not cancer has occurred at a static point in time.

Some cancer types, such as esophageal cancer and brain cancer, do not have corresponding biomarkers. 
On the other hand, ct-DNAs and CTCs are only
detectable after a tumor has formed, and as such, their physical expressions of information, or signals, are typically weak during the early stages of a cancer as their concentrations in the blood are relatively low.

In the Media

Recent Developments

July 29, 2020 - AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests

 AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer Differentiation Analysis (“CDA”) based tests as of July 15, 2020.

AnPac Bio had previously completed more than 169,000 CDA-based tests as of March 31, 2020. From April 1, 2020 to July 15, 2020, the Company completed over 10,000 commercial CDA-based tests and over 1,000 CDA-based tests for research purposes, which increased the cumulative number of CDA-based tests to over 180,000.

“We are honored to have achieved this milestone, which demonstrates the market-wide acceptance of our products. We offer a comprehensive product offering to meet different customers’ needs and to address this large and growing market. Our CDA-based test can detect and assess an individual’s overall risk of having or developing cancers, and a cancer risk assessment report is the final product of the test. The report presents the analytical parameters that our CDA test uses, including the PTF, CTF and overall CDA values,” said Dr. Chris Yu, CEO and Chairman of AnPac Bio.

Dr. Chris Yu continued, “Our CDA-based test is advanced in many ways. Unlike conventional cancer screening and detection approaches such as imaging technology and tissue biopsy, our CDA test uses liquid-based technology to detect the risk of cancer and non-cancerous diseases. It is minimally invasive, side effect-free and highly automated. Because it focuses on changes in cancer-related biophysical properties as a disease progresses, we believe that our CDA test can be used for multiple purposes, including early cancer screening and detection, and assistance in cancer diagnosis, prognosis and recurrence.”

For Full Release: https://www.globenewswire.com/news-release/2020/07/29/2069432/0/en/AnPac-Bio-Completes-Over-180-000-CDA-Based-Cancer-Risk-Assessment-Tests.html

July 13, 2020 - AnPac Bio Completed 1st Half Year with Increased ASP and Revenue

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, pre-announced certain results from the quarter ending 6/30/20. The Company performed 6,500 paid tests in June 2020, which was almost 50% higher than the average monthly paid tests in 2019.  Based on unaudited numbers for the first half of the year in 2020 through 6/30/20, revenue was slightly higher compared to the same period in 2019, while the average selling price (ASP) increased as well over 2019.  AnPac Bio plans to file the 1st half year results on August 28, 2020.

Highlights during the period of the 1st half of 2020:

  • The Company successfully listed on the NASDAQ stock exchange on January 30, 2020.
  • The volume of paid CDA tests picked up significantly starting in late May through the end of June, with June alone recording approximately 6,500 paid tests (50% higher than the monthly average in 2019).
  • The ASP has increased due to higher pricing for new contracts and more favorable distributor mix.
  • Two new products were launched, including a novel immunology test product named ADME (AnPac Defense Medical Examination) and a new cancer test package named APCS (AnPac Pan Cancer Screening) combining CDA technology with ct-DNA method.
  • The San Jose, US lab received CAP certification.
  • The Philadelphia, US lab completed renovation and 1st phase equipment was moved-in.
  • More patents were issued, reaching 128 issued patents in total at the end of June, 2020.
  • Additional hospitals entered into collaborations with the Company in clinical studies, including a study with a leading hospital around coronavirus risks.
  • Continued work on obtaining Class III medical device certification in China and laboratory developed test (LDT) in the US.

AnPac Bio’s CEO, Dr. Chris Yu, commented, “With COVID-19 under control in China, our business has picked up significantly in the second half of May through June.  As businesses have returned to work with a new increased awareness about the importance of health and relevant tests for disease prevention, our paid tests have increased.  In addition, our increased ASP for CDA tests, and as new products are beginning to contribute to revenues, we expect a strong second half of the year in 2020, and overall strong revenue growth for the full year in 2020.”

Dr. Chris Yu continued, “With our successful IPO on the NASDAQ earlier this year, we are now focusing on three major areas, (1) new product development, (2) product commercialization, and (3) sales, with an emphasis on execution. Our results in May and June of this year I believe demonstrate the traction that we are achieving and we are showing real progress in our growth.”

For Full Release:
https://www.globenewswire.com/news-release/2020/07/13/2061236/0/en/AnPac-Bio-Completed-1st-Half-Year-with-Increased-ASP-and-Revenue.html

June 26, 2020 - AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that Frost & Sullivan has recently ranked AnPac Bio number three globally and number one in China in liquid biopsy for both clinical and commercial samples in the year of 2019 in cancer screening. That includes all next generation early cancer screening technologies, including CTC’s (circulating tumor cells), ct-DNA (circulating tumor DNA), exosomes, CDA (cancer differentiation analysis), mRNA (microRNAs), and other emerging technologies. AnPac Bio’s proprietary CDA platform utilizes combination tests which can both screen for overall cancer risk as well as provide cancer location information.

Frost & Sullivan is a leading business consulting firm involved in market research and analysis. According to the report, paid for by AnPac Bio, AnPac increased its position in China and doubled its lead from last year due to the rapidly growing number of paid commercial tests it provides. Compared with data in 2018, AnPac Bio further widened its lead by more than 100% over the number 2 ranked company in China in paid cancer screening tests in 2019. The report further solidifies AnPac Bio as one of the few commercial next generation early cancer screening technologies (cancer risk assessment) using liquid biopsy that is currently in market. The Company announced on May 18, 2020 that it has completed 169, 800 general population screening & clinical research study samples.

AnPac Bio’s CEO, Dr. Chris Yu, commented, “AnPac Bio has continually demonstrated our unique position in the liquid biopsy and cancer screening market. We have designed and commercialized a cancer risk assessment test that will populate the cancer detection market. Our solution has proven to be simple, low-cost, ability to detect early, and thorough, yet just as accurate and effective as the current standards on the market. Over the last ten years, we have laid the foundation to make our tests as widespread and accessible as possible. As a result, we are now becoming one of the most accepted leaders in the next generation of cancer screening and detection. Our approach has proven to be successful and is further validated by the Frost & Sullivan research data.”

For Full Release:
https://www.globenewswire.com/news-release/2020/06/26/2054016/0/en/AnPac-Bio-Ranked-3-in-Liquid-Biopsy-Clinical-Samples-Globally-by-Frost-Sullivan-While-Retaining-1-Position-and-Widening-its-Lead-in-China-in-Cancer-Screening.html

June 22, 2020 - AnPac Bio Launches New Immunology Test Product Line

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that  the Company launched a new immunology test product line in China during the week of June 15, 2020.  This immunology test product line consists of multiple government-approved immunology related tests, and relies on AnPac Bio’s novel multi-level, multi-parameter scientific approach and expertise along with our proprietary algorithms.

Given the evidence of correlation between degradation in human immune system and cancer occurrence and diseases such as COVID-19, there has been increasing interest in immunology related tests and risk assessments. According to market research the immunology related tests’ market potential is estimated at $3 billion per year in China and growing at ~ 20% annually.  Since the launch of AnPac Bio’s immunology test product line last week, it has already attracted a high level of interest from potential customers.

AnPac Bio’s CEO, Dr. Chris Yu, commented, “As a technology visionary and innovator in the field of early stage cancer screening, we are continually committed to developing new technologies and products related to cancer screening or that are synergistic to our technology platform.  Our new immunology test product line is both related to assessment of a range of diseases, including cancer, our multi-level and multi-parameter approach.” 

Dr. Chris Yu continued, “The launch of AnPac Bio’s immunology test product line is expected to significantly strengthen our product portfolio, broaden our customer base and enhance our market position.  As a result, we expect that it will contribute significantly to AnPac Bio’s growth.”

For Full Release:
https://www.globenewswire.com/news-release/2020/06/22/2051263/0/en/AnPac-Bio-Launches-New-Immunology-Test-Product-Line.html

June 19, 2020 - AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has entered into a record, three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management Co., Ltd. in China, which has been a client of the Company for the past two years. This contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021, and 45,000 paid tests in 2022. The total value of the contract is slightly over US$3 million and exceeds the previous contract by more than double the number of paid tests per year.  

AnPac Bio’s CEO, Dr. Chris Yu, remarked, “Our novel cancer screening technology and tests are receiving increasing acceptance from the healthcare market. Due to our CDA tests’ outstanding performance and competitive costs, we expect to see significant continued market opportunities and growth potential in China.”

Dr. Chris Yu continued, “Our ability to continue receiving multi-year sales contracts demonstrates that our novel technology, quality and service have long sustainability with customers in the market place. At the same time, we are pushing ahead with our commercialization plan of CDA cancer screening tests in the US, with on-going commercialization efforts at our San Jose lab and opening of our second lab at Philadelphia.”

For Full Release:
 https://www.globenewswire.com/news-release/2020/06/19/2050704/0/en/AnPac-Bio-Signs-a-Record-Multi-Million-Dollar-Contract-for-Cancer-Screening.html

June 02, 2020 - AnPac Bio Announces Appointment of New Chief Financial Officer

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced the appointment of Mr. Jinqiu (Edwards) Tang as the Chief Financial Officer of the Company, effective June 1, 2020. Mr. Tang will succeed to Ms. Yu (Rain) Zhang, who resigned as the Chief Financial Officer of the Company for personal reasons effective on May 31, 2020.

Mr. Jinqiu (Edwards) Tang has served as AnPac Bio’s Corporate Controller since October 2019. Prior to joining AnPac Bio, Mr. Tang served as a global internal auditor at Natuzzi S.p.A (Italy) from 2016 to 2019. Previously, he worked for Beijing Dongshen CPAs from 2013 to 2016 and Shanghai De’an CPAs from 2011 to 2013, where he provided external audit, finance and tax advisory services across different industries and sectors. He has been a Certified Public Accountant in Australia since 2019. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia in 2007; MBA from Charles Sturt University in Australia in 2009; and his bachelor’s degree in law from Southwest University of Science and Technology in China in 2017.

“I am excited to welcome Edwards to join the management team. His strong financial background will help him to make an immediate impact at AnPac Bio,” said Dr. Chris Yu, the CEO and Chairman of the board of directors of AnPac Bio. “Also, on behalf of our management team and board of directors, I would like to thank Rain for her contributions. I am grateful for all she has done for AnPac Bio during the time she served as our CFO.”

“AnPac Bio has been recognized in the field of early cancer screening and detection, and I’m delighted to be a part of this fantastic organization. I look forward to joining the management team and contributing to AnPac Bio’s future success as the Company progresses to the next phase of its strategy,” said Mr. Tang, the new CFO of AnPac Bio.

For Full Release:
 https://www.globenewswire.com/news-release/2020/06/02/2042596/0/en/AnPac-Bio-Announces-Appointment-of-New-Chief-Financial-Officer.html

May 26, 2020 - AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that another new US patent titled “Apparatus for Improved Disease Detection” was granted to the Company by the United States Patent and Trademark Office on May 20, 2020, which is the second AnPac Bio patent granted this month, and the third in 2020. The new patent covers novel medical device structures, methods, and biophysical related test parameters for improved detection performance. The newly granted patent this week brings the total number of issued and granted AnPac Bio patents to nineteen in the United States.

“AnPac Bio has always focused on technological innovation and building a strong patent and IP portfolio in the space of cancer screening and detection. We will continue to invest aggressively in advanced cancer detection technologies and related intellectual property, and maintain our competitiveness in the space of cancer screening and detection,” said Dr. Chris Yu, CEO and Chairman of AnPac Bio. “Our patent applications in China, the U.S. and nearly 20 other countries and regions throughout the world, if granted, will further enhance our competitive advantage, and will play an important role in the anticipated commercialization of AnPac Bio’s cancer risk assessment test in the U.S.”

Dr. Chris Yu continued, “The newly granted patent strengthens our position in our cancer detection medical device’s [designs and structures, detection methods, novel test parameters, and new reagents, which is expected to further solidify our competitive advantages in the technical space of cancer screening and detection. AnPac Bio’s cancer screening and detection sample size had increased to 169,800, including 42,300 samples from research studies, as of March 31, 2020. AnPac Bio will continue to build a significant database which will provide a major contribution to our understanding of cancer occurrence and help us solve the challenging task of early stage cancer detection.”

For Full Release:
 https://www.globenewswire.com/news-release/2020/05/26/2038559/0/en/AnPac-Bio-Continues-to-Build-Strong-Patent-Portfolio-with-3rd-Patent-Granted-This-Year-in-the-United-States.html

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For AnPac Bio-Medical Science Co., Ltd. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has signed a two month agreement with the Company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has agreed to seventy thousand restricted shares, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.